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Importance of angiogenic action of angiotensin II in the
glomerular growth of maturing kidneys
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Importance of anglogenic action of anglotensin II in the glomerular
growth of maturing kidneys. We studied the effect of three antihyper-
tensive drugs on the growth of glomeruli in four- to five-week-old
Munich-Wistar rats (N = 24), which were undergoing rapid maturation
processes. Young rats were given an angiotensin converting enzyme
inhibitor (ACE!, enalapril, 50 mg/liter drinking water), verapamil (50
mg/liter) or hydralazine (80 mg/liter) or no treatment for six weeks.
Body weight increased comparably in the treatment groups and age-
matched controls, reaching on average 197 11, 214 12 and 198 3
g in ACE!-, verapamil- and hydralazine-treated rats, respectively,
versus 218 6 g in control rats. Glomerular hemodynamic patterns,
including glomerular capillary pressure, measured in maturing rats after
one and six weeks of ACE! treatment were unaffected by ACE!. Mean
planar area of glomeruli (PAmean) achieved was smaller than control in
ACE! rats (6.60 0.20 x l0mm2 vs. 5.37 0.22, respectively, P <
0.005), but not in rats treated with other antihypertensive drugs.
Furthermore, the maturational PAmean increase in rats given ACEI for
six weeks was, on average, only half of that achieved by age-matched
controls not given ACE!, in contrast to normal maturational growth
with hydralazine or verapamil (29% increase in PAmean from normal
baseline in ACEJ vs. 52%, 53% and 59% increases in verapamil,
hydralazine and control, respectively). In contrast, comparable
PAmean values were found in adults with (7.08 0.22 x l03mm2, N
= 6) and without (6.98 0.33 x l03mm2, N = 6) ACEI treatment
given for six weeks. Therefore, ACE!, but not verapamil and hydrala-
zinc, causes growth retardation in maturing glomeruli. The studies
suggest that the rapid growth of glomeruli in maturing kidneys is
dependent upon the angiogenic effect of angiotensin II.
Angiotensin I converting enzyme inhibitors (ACE!) have
been shown to ameliorate the progressive deterioration of
glomerular structure and/or function secondary to experimental
diabetes or subtotal renal ablation [1—4]. Common additional
observations made in these studies are the antihypertensives'
effect to suppress the marked glomerular hypertrophy preced-
ing sclerosis [5, 6]. To determine if these drugs have a similar
anti-hypertrophic effect on glomerular morphology in other
conditions characterized by rapid glomerular growth, we stud-
ied the effect of ACE! and two other structurally-unrelated
antihypertensive drugs on the size of glomeruli of young ani-
mals, which are undergoing a rapid maturational growth.
Of note, angiogenic actions of angiotensin H have been
repeatedly demonstrated in other organ smooth muscle cells
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[7], and most recent preliminary in vitro studies using glomer-
ular cells have also shown angiogenic potential of angiotensin II
in the glomerulus [8]. It has therefore been postulated that
endogenous angiotensin II may play a role in the development
of glomerular hypertrophy in some in situ settings, at least in
part, through mechanism(s) independent of its well known
effect on glomerular hemodynamics. In designing our studies
assessing the effect of ACEI on the structure and hemodynam-
ics of the maturing glomeruli, in which a rapid angiogenic
process is taking place, we speculated that the angiogenic effect
of angiotensin II may be distinguished from its hemodynamic
effect in these otherwise normal healthy animals [9, 10].
Methods
Studies were performed in twenty-four, four- to five-week-
old and twelve more than three-month-old male Munich-Wistar
rats. Animals were allowed free access to regular rat chow and
tap water. Systolic arterial pressure was measured at six weeks
by the tail cuff method [11] in awake animals.
Experimental groups
Experimental protocols employed in the present studies are
illustrated in Figure 1.
Group I: Six week treatment of maturing rats with or without
antihypertensives. Four- to five-week-old rats were placed on
one of the following antihypertensive drugs for six weeks, right
up to the time of micropuncture, as described below.
Group Ia: Enalapril (ACE!, enalapril maleate, Merck Sharp &
Dohme Research Laboratories, Rahway, New Jer-
sey, USA), 50 mg/liter in drinking water (DW) (N
= 7).
Group lb: Verapamil (VPL, isoptin, Knoll, Whippany, New
Jersey, USA), 50 mg/liter DW (N 5).
Group Ic: Hydralazine (HLZ, Sigma Chemical Company, St.
Louis, Missouri, USA), 80 mg/liter DW (N = 5).
Group Id: No antihypertensives (CONT, N 7).
At six weeks Group Ia and Id animals were subjected to the
micropuncture assessment of glomerular hemodynamics, fol-
lowed by the morphometric analysis of glomeruli on fixed
kidney tissues as described below. In a separate group of six
young rats (Group Ia') given enalapril as above, micropuncture
assessment was done after one week of treatment to assess the
early hemodynamic pattern with this treatment. Kidneys from
four- to five-week old age-matched rats, not shown in Figure 1
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(N = 6), were examined morphometrically to determine normal
glomerular size at the onset of the study.
Group 2: Six week treatment of adult rats with an angiotensinI converting enzyme inhibitor. Adult rats (>3 months old) were
placed on one of the following experimental regimens for six
weeks, right up to the time of micropuncture, as described
below.
Group 2a: Enalapril, 50 mg/liter in drinking water (DW) (N =
6).
Group 2b: No antihypertensives (N = 6).
A separate group of adult rats (N = 4, >3 months old) was
treated with enalapril, 50 mg/liter drinking water as Group 2a,
for one week, and plasma renin and angiotensin converting
enzyme activities determined to verify that this dose indeed has
biologic activity in adult rats. Control rats (N = 4) received no
drug. Plasma renin activity was markedly elevated in enalapril
treated rats versus control, on average 96 39 versus 25 7
ng/ml, while angiotensin converting enzyme was substantially
reduced below normal, on average 7.4 0.1 versus 22.2 0.7
U/liter, respectively (P < 0.0005).
At six weeks animals were sacrificed for the morphometric
analysis of glomeruli specified below.
Renal clearance and micropuncture measurements
Animals were anesthetized with an intraperitoneal injection
of mactin (Byk, Gulden Konstanz, FRG; 100 mg/kg body wt,
i.p.), placed on a temperature-regulated micropuncture table,
and prepared as previously described [12]. Briefly, following
tracheostomy, indwelling polyethylene catheters (PE-50, Clay
Adams, Parsippany, New Jersey, USA) were placed into the
left and right jugular veins for infusion of plasma, inulin and
para-aminohippurate (PAH). The left femoral artery was cath-
eterized to monitor mean systemic arterial pressure (MAP),
measured by electronic transducer (Model p23XL, Gould Inc.,
Cleveland, Ohio, USA) connected to a recorder (Model 2200S,
Gould Inc.). The left ureter was cannulated with PE-lO catheter
for urine collections. The left kidney was suspended on a Lucite
holder, its surface illuminated with a fiberoptic light source, and
bathed with 0.9% NaCl. Volume losses consequent to surgical
preparation were replaced with plasma, infused in a volume
equal to 1% of body weight over 30 minutes, followed by a
maintenance infusion at the rate of 1.2 mI/hr. A solution of 10%
inulin and 1.0% PAH in 0.9% NaCI was infused throughout the
duration of the experiment at the rate of 1.2 mI/hr.
After a 60-minute equilibration period, clearance and micro-
puncture measurements were made as detailed below. Exactly
timed (1 to 2 mm) samples of tubule fluid were collected from
surface proximal convolutions for the determinations of flow
rate and inulin concentration for calculation of single nephron
glomerular filtration rate (SNGFR). Coincident with the tubule
fluid collections, femoral arterial blood was obtained for the
determination of hematocrit and plasma concentrations of pro-
tein, inulin and PAH. Whenever appropriate, two or three
samples of urine from the kidney were collected for determina-
tions of flow rate, inulin and PAH concentrations, which were
used in the calculation of whole kidney GFR and effective renal
plasma flow rate (ERPF).
Hydraulic pressures were monitored in accessible surface
structures with a continuous-recording servo-null micropipette
transducer system (Model 3, Instrumentation for Physiology
and Medicine, San Diego, California, USA). Micropipettes with
outer diameter of I to 2 tm containing 2.0 MNaCI were used.
Hydraulic output from the servo-null system was converted
electronically to a recorder (Model 2200S, Gould) by means of
a pressure transducer. Direct measurements of time-averaged
Groupla Group lb Groupic Groupid
Fig. 1. Schematic presentation of the protocols employed in the present study.
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Table 1. Whole body parameters in animals with or without
antihypertensive treatment
Animal groups
Body wt
g
Kidn
wet
g
ey wt
dry
g
Group Ia (Maturing) 197 0.72a 0.16a
ACE!, N = 7
Group lb (Maturing) 214 0.81 0.l7a
VPL, N = 5
Group Ic (Maturing) 198 0.79 0.1?
HLZ, N = 5
Group Id (Maturing) 218 0.86 0.19
No-Tx, N = 7
Group 2a (Adult) 226 1.00 —
ACEI, N = 6
Group 2b (Adult) 242 1.04 —
No-Tx, N = 6
Values are expressed as mean SEM. Abbreviations are: Body wt,
body weight; Kidney wt, kidney weight; Maturing, 4—5 week old at the
onset of experiments; Adult, >3 month old at the onset of experiments;
ACE!, Angiotensin converting enzyme inhibitor, enalapril; VPL, ver-
apamil; HLZ, hydralazine; No-Tx, control rats not given ACE!.
a P < 0.05 vs. Group Id. Statistical comparison is not made between
Groups I and 2.
hydraulic pressures were recorded in single capillaries of sur-
face glomeruli (PGc), Bowman's space, and surface efferent
arteriole. For estimation of oncotic pressures of plasma enter-
ing and leaving glomerular capillaries, protein concentrations of
afferent (CA) and efferent (CE) arterioles were determined by
analyzing femoral arterial and surface efferent arteriolar
plasma, respectively, using the fluorometric method previously
described [13, 14].
Histological study
Kidneys were immersion fixed in 10% buffered formalin,
routinely processed and embedded in paraffin. Sections of 3 j.m
thickness were made, stained with periodic acid-Schiff, and
examined microscopically (Olympus BH2, Olympus Optical
Co. Ltd., Tokyo, Japan).
Mean planaE area of glomeruli was assessed for young and
adult on sections of control and the treatment group kidneys at
six weeks and on kidneys from normal young rats at baseline (at
0 weeks). The planar area of each glomerular capillary tuft was
determined on these sections using a computerized planimeter
(Micro-plan II, Monsanto Corp., Natick, Massachusetts, USA)
and traced at '—380x magnification using a camera lucida
attachment. The Outline of the entire glomerular corpuscle was
measured. Extreme tangential cuts of glomeruli, as evidenced
by a section showing only discontinuous, separate capillary
loops, were excluded. The values of these planar areas, thus
measured in 50 to 60 glomeruli, were averaged for each thin
section specimen.
Analytic
The volume of fluid collected from individual proximal tu-
bules by micropuncture was estimated from the length of the
fluid column in a constant-bore capillary tube of known internal
diameter. Plasma and urine inulin concentrations were assayed
by the macroanthrone method of FUhr, Kaczmarczyk and
KrOttgen [15]. Inulin concentrations in tubule fluid was deter-
mined by the method of Vurek and Pegram [16]. PAH concen-
tration in plasma and urine was measured by the method of
Bratton and Marshall, as modified by Smith et al [17].
Statistical analysis
Results are expressed as mean 1 SEM. Comparisons be-
tween two groups were made using the unpaired t-test. Data
from multiple groups were compared using one-way ANOVA
followed by multiple comparisons by the Bonferroni method
[18]. The results were deemed statistically significant when the
P value was <0.05.
Results
Systemic and whole kidney parameters
Data for body weight and dry and wet kidney weight mea-
sured at the completion of study are shown in Table 1. Thus,
Group Ia, Ib, Ic and Id maturing animals were statistically
indistinguishable in body weight regardless of the treatment
given during the preceding six week period, Wet kidney weight
was significantly less than control only for Group la, whereas
dry kidney weight was significantly less in all the treated rats
versus control. Group 2a adult animals given ACE! and Group
2b adult control animals were comparable with regards to body
and kidney weight. Systemic systolic blood pressure at six
weeks was similar between Groups la, lb and id (110 6mm
Hg, 113 5, and 109 6, respectively), whereas Group Ic had
higher level versus control Group ld and ACE! Group Ia (123
1 mm Hg, P < 0.0005 vs. Group Id, P < 0.005 vs. Group la).
Systemic blood pressure in Group 2A adult ACE! was normal
(119 5mm Hg).
Whole kidney and glomerular hemodynamic parameters
Average values for several pertinent whole kidney and gb-
merular hemodynamic parameters measured in maturing rats of
Groups Ia and id are summarized in Table 2. Thus, values for
mean systemic arterial pressure, MAP, were modestly but
significantly lower in Group la animals given ACEI than Group
ld control rats of the same age, on average by 12 mm Hg. Like
those for whole kidney GFR and ERPF, mean values for
SNGFR and SNFF were comparable in Group Ia ACE! rats
(29.7 2.1 nI/mm and 0.23 0.02, respectively) and Group Id
control rats (31.6 1.7 nI/mm and 0.24 0.01, respectively) so
that QA values were calculated to be also comparable between
the two groups. Values for other gbomerular microcirculatory
parameters were also comparable between Group la ACE! and
Group Id control rats, demonstrating the typical patterns seen
in rats of Munich-Wistar strain at their age [10, 19]. Thus, in
Groups Ia and Id values for PGC averaged 51.1 1.3 and 48.7
0.5 mm Hg, respectively. Values of arterial plasma protein
concentration, CA, were similar (Table 2). Likewise, values for
affererit and efferent arteriolar resistances were comparable
between the two groups. As shown in Table 3, values for body
weight, mean systemic arterial pressure and P0 in Group Ia'
rats after one week of enalapril showed patterns indistinguish-
able from those measured in age-matched rats previously re-
ported by us [10]. Exception to these resemblances in glomer-
ular microcirculatory dynamics between the ACEI-treated and
untreated maturing rats was the value of glomerular capillary
ultrafiltration coefficient, K. Thus, values for K in Group Ia
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Table 2. Whole kidney and glomerular hemodynamic parameters at 6 weeks in maturing
enzyme inhibitor treatment
animals with or without angiotensin I converting
RA RE
Animal groups
MAP
mm Hg
GFR ERPF
mI/mm
SNGFR QA P0
nI/mm SNFF mm Hg
J0x1O dyne.sec.
cm5 CAgIdi
aKr
n!/(sec mm Hg)
Group la 103 0.92 3.37 29.7 135 0.23 51.1 1.84 1.29 6.1 0.057
ACEI ±2 ±0.13 ±0.38 ±2.1 ±13 ±0.02 ±1.3 ±0.22 ±0.16 ±0.1 ±0.008
(N = 6 rats)
Group ld 115 0.95 3.87 31.6 132 0.24 48.7 2.22 1.09 6.2 0.078
No-Tx ±5 ±0.04 ±0.20 ±1.7 ±7 ±0.01 ±0.5 ±0.21 ±0.05 ±0.0 ±0.008
(N = 6 rats)
P value <0.05 NS NS NS NS NS NS NS NS NS <0.05
Values are expressed as mean ± SEM. MAP, Mean arterial pressure; GFR, whole kidney glomerular filtration rate; ERPF, effective renal plasma
flow rate; SNGFR, single nephron glomerular filtration rate; QA glomerular plasma flow rate; SNFF, single nephron filtration fraction; POC,
glomerular capillary hydraulic pressure; RA, afferent arteriolar resistance; RE, efferent arteriolar resistance; CA, systemic arterial plasma protein
concentration; Kr, glomerular capillary ultrafiltration coefficient; ACE!, angiotensin converting enzyme inhibitor, enalapril; No-Tx, control rats not
given antihypertensives; NS, P  0.05. Filtration pressure equilibrium was achieved in 2 ACE! rats and 3 No-Tx rats.
a Unique and minimum Kf values were pooled to obtain these average values.
Table 3. Glomerular hemodynamic parameters at 1 week in maturing
animals with or without angiotensin I converting enzyme inhibitor
treatment
Animal groups
Body wt
g
MAP
mm
PGC
Hg
Group la' 106 87 38
ACE! 1 week ±3 ±2 ±0.8
(N = 6 rats)
Control 96 78 37
No Tx (N = 6 rats) ±5 ±5 ±2
P value NS NS NS
Values are expressed as mean ± SEM. Abbreviations are: Body wt,
body weight; MAP, mean arterial pressure; P0w, glomerular capillary
pressure. Control rat data are from our reference [10]. NS, P > 0.05.
rats given ACE! for six weeks averaged 0.057 ± 0.008 nIl
(sec mm Hg), a value 27% below the average value measured
in age-matched Group ld control rats (0.078 ± 0.008, P < 0.05).
Glomerular morphology
Figure 2 summarizes values for PAmean determined at the
completion of study in all experimental groups. Baseline
PAmean at 0 weeks in young rats was 4.16 ± 0.24 X 103mm2
(Fig. 2A, horizontal line). Not surprisingly, all young rats
showed continued growth after six weeks. Values for PAmean
were smaller, but approached the adult size, in Group ld
control maturing (Fig. 2A) versus Group 2b control adult rats
(Fig. 2B), on average 6.60 ± 0.20 x 103mm2 versus 6.98 ±
0.33, respectively. Of note, within Group 1 maturing animals,
but not in the adult, there was a significant difference in
PAmean among subgroups given different treatment (Fig. 2A).
Thus, PAmean averaged 5.37 ± 0.22 x 103mm2, 6.32 ± 0.26,
6.37 ± 0.09 and 6.60 ± 0.20, respectively, in Group la (ACE!),
lb (VPL), Ic (HLZ) and ld (No-Tx) maturing rats. Thus,
glomerular growth of Group lb VPL and Group lc HLZ rats
was comparable to Group ld control maturing rats, with in-
creases of 52%, 53% and 59% over 0 week baseline values,
respectively. In contrast, Group la rats given ACE! had signif-
icantly smaller PAmean (P < 0.005 ACE! vs. No-Tx; P < 0.025
ACE! vs. VPL or HLZ) and showed only half of the growth
observed in the other groups (29% increase over baseline
PAmean). In adults, by contrast, six weeks of ACEL treatment
did not affect glomerular size: PAmean values were comparable
between Group 2a and 2b, averaging 7.08 ± 0.22 x 103mm2
versus 6.98 ± 0.33, respectively (P > 0.4).
Discussion
The renin-angiotensin system is active during intrauterine
life, and remains so in the neonate of several mammalian
species as compared to the adult [20—22]. Physiological role for
this active renin-angiotensin system during the early periods of
life, however, has not been elucidated [23]. In fact, the finding
of Jose et al [9] that the prevailing level of RBF in young
animals did not increase after antagonism of angiotensin II was
taken to indicate that this hormone does not participate in
determining the high renal arteriolar vascular tone characteriz-
ing young Animals. Evidence that the same notion applies also
to the five- to six-week-old maturing rats in the present study
has recently been obtained in a series of experiments conducted
by us and others. Both plasma renin activities [10] and angio-
tensin II concentrations [24] were shown to reach similarly low
levels as those of adults by five to six weeks of age. Yet, in
response to a given amount of exogenous angiotensin II,
vasoconstrictive response of young animals is remarkably less
than that of adults [10, 25]. In contrast to the lack of evidence
of vasoconstrictive action of angiotensin I! in maturing animals,
recent studies suggest that angiotensin may have an important
role in the growth and differentiation in the young animal. In
this regard, angiotensin I! receptors are highly expressed in the
rat fetus [5]. Studies of the augmented expression of renin
mRNA found maximal levels at the time of most marked
nephrogenesis in the newborn rat [6]. Our observations further
point to the importance of angiotensin II in glomerular matura-
tional growth after completion of nephrogenesis in the rat.
Administration of angiotensin I converting enzyme inhibitor
in normal adult rats regularly fails to induce alteration in
glomerular circulatory dynamics [26, 27]. Therefore we verified
that the dose given indeed has biologic effect in the adult rats,
by showing inhibition of angiotensin converting enzyme and
elevated plasma renin levels in adult rats given ACE!. Given the
observations made in our laboratories [10] that the renin-
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Fig. 2. Values for mean planar area (PAmean) neasured in various
experimental groups at the completion of study. The horizontal line in
A represents normal PAmean at 0 weeks (that is, 4 to 5 week old).
Average increases over this baseline (100%) PAmean were calculated to
be 29%, 52%, 53% and 59%, respectively, for ACEI, VPL, HLZ and no
treatment (No-TX) control rats.
angiotensin system reaches the adult low level by age approx-
imately five weeks in normal rats, the observed lack in the
present study of hemodynamic effect on maturing glomeruli is
also not surprising. The only parameter found to be different
between these groups was glomerular capillary ultrafiltration
coefficient.' Given that glomerular capillary ultrafiltration coef-
ficient is the product of filtering surface area and hydraulic
conductivity of the glomerular capillary wall, the observed K1
reducing effect of chronic administration of ACE! is in concert
with our histological findings that Group la animals given ACE!
had glomerular planar area substantially less than that of Group
id rats not given ACE!. This parallelism between Kf and
glomerular planar area is reminiscent of our previous findings
that chronic feeding of low protein content diet in Munich-
Wistar rats of four to five weeks of age resulted in parallel
reduction of K and glomerular planar area when compared to
age-matched control animals in the absence of appreciable
influence on glomerular capillary pressure 1281. This effect of
low protein diet on glomerular size and Kf may be at least in
part through modulation of renin-angiotensin system, since it
has recently been shown that the dietary protein intake modu-
lates renin mRNA expression 129]. Thus, angiotensin II has
both hemodynamic and angiogenic actions, and inhibition of
Numerically, P was slightly higher in group Ia ACE! vs. group Id
control, 36.6 1.0 vs. 34.5 0.5 (P>0,4), despite lower average value
for SNGFR in the former. Since the relationship between SNGFR and
its determinants is not a simple linear one, P values for each parameter
can vary, as in this study, where P was less than 0.05 for K1 only.
ACE will therefore modify both of these factors: the former
hemodynamic effect occurs acutely while the angiogenic action
is chronic. Taken together, our studies with chronic ACET
suggest that angiotensin II is indeed important in maturing
kidneys, specifically, in terms of its role to participate in the
growth of glomeruli, which takes place at a rapid rate in these
animals.
In contrast to these effects found with ACE!, both VPL and
HLZ failed to affect the maturational growth of glomeruli,
suggesting that ACEI's suppressive effect on the glomerular
growth is not shared with other antihypertensive drugs which
are structurally unrelated to ACE!. In fact, glomerular planar
area of HLZ rats, relative to their slightly smaller dry kidney
weight, was on average even higher than that of control treated
rats. In view of the well-known effect of HLZ to activate the
renin-angiotensin system [301, our findings with HLZ are fur-
ther supportive of the notion that angiotensin II is involved in
maturational growth. Nevertheless, one may argue that ii
higher dosages of VPL and HLZ were given to the maturing
animals, they, too, may have caused similar retardation in
glomerular growth.
We are, however, intrigued by another possibility which is
also consistent with the contention that the physiological sig-
nificance of angiotensin II in maturing kidneys resides primarily
in its angiogenic rather than vasoconstrictive action. The read-
ers may recall that the two final functional expressions of
angiotensin H's actions, that is, vasoconstriction and angiogen-
esis, share common receptor and immediate post-receptor
signal transduction processes, yet the intermediary metabolites
directly linked to vasoconstriction and angiogenesis are be-
lieved to be different beyond the hydrolysis of phosphatidylino-
sitol bisphosphate (PIP2). Thus, the immediate products of
PIP2 that is, inositol I ,4,5-trisphosphate (1P3) and diacylglyc-
erol (DAG), are believed to be linked to contraction and
angiogenesis, respectively [7]. It is therefore conceivable that
unlike immature animals, local level of angiotensin II in base-
line condition of adult animals is extremely low, or that normal
mature animals lack the post-DAG processes which lead to
glomerular growth.
1P3, the other product of PIP2 leads to mobilization of calcium
from both intracellular and extracellular sources. Hydralazine
and verapamil's [31] vasodilatory actions are channeled through
their capacity to interfere with these processes, which are
crucial steps for the initial and sustained contractility of the
smooth muscle cells, respectively. Therefore it is conceivable
that angiogenic actions of angiotensin II, and potentially other
growth promoting substances, which are in part independent of
this intracellular calcium transfer, may remain intact during the
administration of VPL or HLZ. In support of this notion
prenatal and postnatal hydralazine treatment was found not to
prevent renal vessel wall thickening in genetically spontane-
ously hypertensive rats despite its effectiveness to ameliorate
the characteristic hypertension [32]. Verapamil administration,
in a certain dosage, in subtotally nephrectomized rats was
actually found to augment glomerular deterioration character-
istic of remnant nephrons 133]. In contrast, converting enzyme
inhibitor (captopril) in one-kidney one-clip hypertensive rats
resulted in decreased arteriolar cross-sectional wall area and
also a decrease in the number of small arterioles, although
ACEL was without effect on the systemic hypertension. Similar
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results were seen in ACEI-treated normal rats, indicating that
ACE! resulted in inhibition of vascular growth independent of
effects on hypertension [34]. Experiments in a rat model of
hypertensive cardiac hypertrophy comparing dihydralazine, the
calcium antagonist nifedipine and the ACE! ramipril in equipo-
tent antihypertensive dosages, found that only the ACEI pre-
vented and also caused regression of the cardiac hypertrophy.
Even lower, non-antihypertensive doses of the ACE! were
effective in this regard, further indicating the role of angiotensin
II in vascular growth separate from its vasoconstrictive effects
[35]. In another hypertensive animal model, ACE! also re-
versed the hypertrophy of vascular smooth muscle cells while
absolute collagen content remained elevated [36]. This consid-
eration of angiotensin Il-induced vasoconstriction and angio-
genesis, which are regulated by different second messengers,
raises an interesting possibility that warrants future investiga-
tion.
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